Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

inhalational anthrax - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

inhalational anthrax

MONDO:0016595

Also known as:inhalation anthrax diseasepulmonary anthraxrespiratory anthrax

Find Clinical TrialsTrials

Overview

A rare acute systemic infection caused by the inhalation of Bacillus anthracis spores (e.g. through infected animal products, bioterrorism) and characterized by an initial stage where patients present with non specific symptoms (fever, cough, chills, fatigue) that is followed by an acute phase during which hemorrhagic mediastinitis occurs that can progress into meningitis, gastrointestinal involvement, and refractory shock, that can be fatal, if left untreated.

Treatments2 FDA approved

Clinical Trials2 registered

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for inhalational anthrax, including OBILTOXAXIMAB (ANTHIM, approved 2016) and CIPROFLOXACIN (CIPRO, approved 1997). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

2 clinical trials registered. Interventions under study include drug therapy and biologic therapy. Research is primarily industry-sponsored.

17 publications have been identified in PubMed for inhalational anthrax. Research spans Case Report / Case Series (35%), Basic Science / Preclinical (35%), and Gene Therapy / Novel Therapeutics (18%).

Research Type	Count	% of Total
Patient case studies	6	35%

Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 6:36 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:247257

GARD

Genetic and Rare Diseases Info Center

GARD:20657

Questions for Your Care Team

→What are the benefits and potential side effects of ANTHIM for managing inhalational anthrax?
→Are any of the 2 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages	L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages	iNtRON Biotechnology, Inc.	2018	—	Designated
human monoclonal anti-PA antibody	human monoclonal anti-PA antibody	Emergent Product Development Gaithersburg, Inc.	2010	—	Withdrawn
anthrax immune globulin	anthrax immune globulin	Emergent Biosolutions, Inc.	2009	—	Withdrawn

Kisho

inhalational anthrax

Overview

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

inhalational anthrax

Overview

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications